

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)
(Use several sheets if necessary)ATTY. DOCKET NO.
UCAL203SERIAL NO. 09/828,505
Confirmation No. 6822

APPLICANT

Raz et al.

FILING DATE

April 6, 2001

GROUP

1645

RECEIVED
JUL 26 2001

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	File Date If Appropriate
QN	AA 5,736,524	04/07/1998	Content et al.			
I	AB 5,780,448	07/14/1998	Davis			
I	AC 6,194,388	02/27/2001	Krieg et al.			
QN	AD 6,207,646	03/27/2001	Krieg et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No
QN AE WO 96/02555A1	02/01/1996	PCT			
I AF WO 98/16247	04/23/1998	PCT			
I AG WO 98/18810	05/07/1998	PCT			
QN AH WO 00/16804	03/30/2000	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

QN	AI	Fard et al. (1993) "T cell epitopes of the major fraction of rye grass Lolium perenne (Lol p I) defined using overlapping peptides in vitro and in vivo. I. Isoallergen clone1A." Clin. Exp. Immunol., Vol. 94:111-116
I	AJ	Ishioka et al. (1999) "Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes." The Journal of Immunology, Vol. 162:3915-3925
I	AK	Kim et al. (1997) "Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells." Gene, Vol. 199:293-301
I	AL	Krieg et al. (1998) "The role of CpG dinucleotides in DNA vaccines." Trends in Microbiology, Vol. 6(1):23-27
I	AM	McCluskie et al. (1999) "Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates." Molecular Medicine, Vol. 5:287-300
I	AN	McWeeney et al. (1999) "Codon usage bias and base composition in MHC genes in humans and common chimpanzees." Immunogenetics, Vol. 49:272-279
I	AO	Rafnar et al. (1991) "Cloning of Amb a I (Antigen E), the Major Allergen Family of Short Ragweed Pollen." Journal of Biol. Chem., Vol. 266(2):1229-36
I	AP	Raz et al. (1996) "Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization." Proc. Natl. Acad. Sci. USA, Vol. 93:5141-5145
QN	AQ	Roman et al. (1997) "Gene immunization for allergic disorders." Springer Semin Immunopathol., Vol. 19:223-232

EXAMINER

DATE CONSIDERED

1/23/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) (Use several sheets if necessary)		ATTY. DOCKET NO. UCAL203		SERIAL NO. 09/828,505 Confirmation No. 6822	
		APPLICANT Raz et al.			
		FILING DATE April 6, 2001		GROUP 1645	
QN	Shiver et al. (1995) "Cytotoxic T Lymphocyte and Helper T Cell responses following HIV Polynucleotide Vaccination." <i>Annals of the New York Academy of Sciences</i> , Vol. 772:198-208				
QN	AS Weeratna et al. (1998) "Reduction of Antigen Expression from DNA Vaccines by Coadministered Oligodeoxynucleotides." <i>Antisense & Nucleic Acid Drug Development</i> , vol. 8:351-356				
QN	AT Zolotukhin et al. (1996) "A "Humanized" Green Fluorescent Protein cDNA Adapted for High-Level Expression in Mammalian Cells." <i>Journal of Virology</i> , Vol. 70(7):4646-4654				


F:\forms\word 2k forms\form PTO-1449.doc

RECEIVED

JUL 26 2001

TECH CENTER 1600/2900

EXAMINER 	DATE CONSIDERED 4/23/03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Please type a plus sign (+) inside this

COPY OF PAPERS
ORIGINALLY FILED

See Paper #9

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/828,505
		Filing Date	April 6, 2001
		First Named Inventor	RAZ, EYAL
		Group Art Unit	1645
Examiner Name	To Be Assigned		
Sheet 1 of 1	Attorney Docket Number	UCAL-203	

RECEIVED

AUG 08 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
QW		LEITNER, et al. "DNA and RNA-based vaccines: Principles, progress, and prospects", Vaccine, (1999) Vol. 18: 765-777.	

Examiner Signature		Date Considered	1/23/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.